drugset / Trial / NCT01178411
An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols
NaSingle-groupOpen-labelTreatment
Summary
This is an extension study that will allow participants to continue to receive study therapy when the original studies into which they were enrolled have reached their designated end-dates. This extension study is designed to further evaluate the safety and tolerability of tivantinib (ARQ 197) monotherapy or in combination with other drug(s) when given to participants who tolerated previous treatment well and may benefit from the continuing treatment.
Timeline
- Start
- 2010-08-31
- Primary completion
- 2019-01-14
- Completion
- 2019-01-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tivantinib | Small molecule | 360 mg | Oral |
| Background | Cetuximab | Monoclonal antibody | — | — |
| Background | Erlotinib | Small molecule | — | — |
| Background | Gemcitabine | Small molecule | — | — |
| Background | Irinotecan | Small molecule | — | — |
| Background | Pemetrexed | Small molecule | — | — |
| Background | Sorafenib | Small molecule | — | — |
| Background | docataxel | Unknown | — | — |